Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA

Biochemical Pharmacology

Volumn 70, Issue 12, 2005, Pages 1717-1725

  Meczes, Emma L ^a   Azim Araghi, Ali ^a,c   Ottley, Christopher J ^b   Pearson, D Graham ^b   Tilby, Michael J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b DURHAM UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cisplatin; DNA adduct; ICP MS; Immunoassay; Ion exchange chromatography; Oligonucleotide

Indexed keywords

ADENINE; CISPLATIN; DEOXYRIBONUCLEOTIDE; DNA ANTIBODY; GUANINE; MONOCLONAL ANTIBODY; OLIGODEOXYNUCLEOTIDE; OLIGONUCLEOTIDE; POLYDEOXYRIBONUCLEOTIDE; PROTEIN HYDROLYSATE; THYMINE;

ANTIGEN RECOGNITION; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; DNA ADDUCT; DNA SEQUENCE; DRUG DNA INTERACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOREACTIVITY; ION EXCHANGE CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, ION EXCHANGE; CISPLATIN; DNA ADDUCTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; OLIGODEOXYRIBONUCLEOTIDES;

EID: 27744486018     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.09.025     Document Type: Article

References (44)

1. R.M. Santella Immunological methods for detection of carcinogen - DNA damage in humans Cancer Epidemiol Biomarkers Prev 8 1999 733 739
2. M.J. Tilby, C. Johnson, R. Knox, J. Cordell, J.J. Roberts, and C.J. Dean Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody Cancer Res 51 1991 123 129
3. B. Peng, M.J. Tilby, M.W. English, L. Price, Pearson ADJ, and A.V. Boddy Platinum-DNA adduct formation in peripheral blood leucocytes of children in relation to pharmacokinetics following cisplatin and carboplatin therapy Br J Cancer 76 1997 1466 1473
4. S. Ghazal-Aswad, M.J. Tilby, M. Lind, N. Baily, D. Sinha, and A.H. Calvert Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels Ann Oncol 10 1999 329 334
5. G.J. Veal, E. Dias, E. Price, A. Parry, J. Errington, and J. Hale Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leucocytes of children receiving cisplatin therapy Clin Cancer Res 7 2001 2205 2212
6. H.J. Cross, M.J. Tilby, J.K. Chipman, D.R. Ferry, and A. Gescher Effect of quercetin on the genotoxic potential of cisplatin Int J Cancer 66 1996 404 408
7. D.L. Evans, M.J. Tilby, and C. Dive Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation Cancer Res 54 1994 1596 1603
8. Fichtinger-Schepman A-MJ, Welters MJP, van Dijk-Knijnenburg HCM, van der Sterre MLT, Tilby MJ, Berends F, et al. Detection of adducts formed upon treatment of DNA with cisplatin and carboplatin. In: Pinedo HM, Schornagel JH, editors, Platinum and other metal coordination compounds in cancer chemotherapy, vol. 2. Proceedings of the 7th international symposium, Amsterdam, 1995. New York and London: Plenum Press; 1996. p. 107-19.
9. B.E. Deverman, B.L. Cook, S.R. Manson, R.A. Niederhoff, E.M. Langer, and I. Rosova Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage Cell 111 2002 51 62
10. I.U. De Silva, P.J. McHugh, P.H. Clingen, and J.A. Hartley Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin Nucleic Acids Res 30 2002 3848 3856
11. K.J. Mellish, C.F. Barnard, B.A. Murrer, and L.R. Kelland DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines Int J Cancer 62 1995 717 723
12. B.E. Deverman, B.L. Cook, S.R. Manson, R.A. Niederhoff, E.M. Langer, and I. Rosova Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage Cell 111 2002 51 62
13. D.A. Solomon, M.C. Cardoso, and E.S. Knudsen Dynamic targeting of the replication machinery to sites of DNA damage J Cell Biol 166 2004 455 463
14. C.J. McGurk, P.J. McHugh, M.J. Tilby, K.A. Grimaldi, and J.A. Hartley Measurement of covalent drug-DNA interactions at the nucleotide level in cells at pharmacologically relevant doses Methods Enzymol 340 2001 358 376
15. A. Azim-Araghi, C.J. Ottley, D.G. Pearson, and M.J. Tilby Structures of atypical platinum-DNA adducts in certain resistant lung cancer lines Proc Am Assoc Cancer Res 43 2002 262
16. M.J. Tilby Production of monoclonal antibodies for the detection of chemically modified DNA: methods in molecular biology M. Manson Immunochemical protocols vol. 10 1992 Humana Press 321 328
17. H. McCartney, A.M. Martin, P.G. Middleton, and M.J. Tilby Antibody recognition of melphalan adducts characterised using immobilized DNA: enhanced alkylation of G-rich regions in cells compared to in vitro Chem Res Toxicol 14 2001 71 81
18. A.-M.J. Fichtinger-Schepman, H.C.M. van Dijk-Knijnenburg, S.D. van der Velde-Visser, F. Berends, and R.A. Baan Cisplatin- and carboplatin-DNA adducts: is Pt-AG the cytotoxic lesion? Carcinogenesis 16 1995 2447 2453
19. G. Kallansrud, and B. Ward A comparison of measured and calculated single- and double-stranded oligodeoxynucleotide extinction coefficients Anal Biochem 236 1996 134 138
20. S. Ghazal-Aswad, A.H. Calvert, and D.R. Newell A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve Cancer Chemother Pharmacol 14 1996 800 805
21. M.J. Tilby, J.M. Styles, and C.J. Dean Immunological detection of DNA damage caused by melphalan using monoclonal antibodies Cancer Res 47 1987 1542 1546
22. A.-M.J. Fichtinger-Schepman, J.L. van der Veer, J.H.J. den Hartog, P.H.M. Lohman, and J. Reedijk Adducts of the drug cis-diamminedichloroplatinum(II) with DNA: formation, identification and quantitation Biochemistry 24 1985 707 713
23. A. Azim-Araghi, C.J. Ottley, D.G. Pearson, and M.J. Tilby Combination of ICP-MS and ion exchange chromatography permits analyses of specific cisplatin DNA modifications formed in cancer cells Plasma source mass spectrometry 2003 Special Publications, Royal Society of Chemistry p. 66-73
24. A.-M.J. Fichtinger-Schepman, R.A. Baan, A. Luiten-Schuite, M. van Dijk, and P.H.M. Lohman Immunochemical quantitation of adducts induced in DNA by cis-diamminedichloroplatinum(II) and analysis of adduct-related DNA-unwinding Chem Biol Interact 55 1985 275 288
25. E. Reed, S. Gupta-Burt, C.L. Litterst, and M.C. Poirier Characterization of the DNA damage recognised by an antiserum elicited against cis-diamminedichloroplatinum(II)-modified DNA Carcinogenesis 11 1990 2117 2121
26. A.-M.J. Fichtinger-Schepman, R.A. Baan, and F. Berends Influence of the degree of DNA modification on the immunochemical determination of cisplatin-DNA adduct levels Carcinogenesis 10 1989 2367 2369
27. A. Gelasco, and S.J. Lippard NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin Biochemistry 37 1998 9230 9239
28. S. Mansy, B. Rosenberg, and A.J. Thomson Binding of cis- and trans-dichlorodiammineplatinum(II) to nucleosides. Part I: location of the binding sites J Am Chem Soc 95 1973 1633 1640
29. S. Mansy, G.Y.H. Chu, R.E. Duncan, and R.S. Tobias Heavy metal nucleotide interactions. Part 12: competitive reactions in systems of four nucleotides with cis- or trans-diammineplatinum(II). Raman difference spectrophotometric determination of the relative nucleophilicity of guanosine, cytidine, adenosine, and uridine monophosphates as well as the analogous bases in DNA J Am Chem Soc 100 1978 607 616
30. A. Eastman Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II) Biochemistry 22 1983 3927 3933
31. A. Eastman Re-evaluation of interaction of cis- dichloro(ethylenediamine) platinum(II) with DNA Biochemistry 25 1986 3912 3915
32. F.J. Dijt, A.-M.J. Fichtinger-Schepman, F. Berends, and J. Reedijk Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts Cancer Res 48 1988 6058 6062
33. A.-M.J. Fichtinger-Schepman, S.D. van der Velde-Visser, H.C.M. van Dijk-Knijnenburg, A.T. van Oosterom, R.A. Baan, and F. Berends Kinetics of the formation and removal of cisplatin-DNA adducts in blood and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation Cancer Res 50 1990 7887 7894
34. D. Wang, and S.J. Lippard Cellular processing of platinum anticancer drugs Nat Rev Drug Discov 4 2005 307 320
35. R. Knox, F. Friedlos, D.A. Lydall, and J.J. Roberts Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis- diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA Cancer Res 46 1986 1972 1979
36. A.C.M. Plooy, A.-M.J. Fichtinger-Schepman, H.H. Schutte, M. van Eijk, and P.H.M. Lohman The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques Carcinogenesis 6 1985 561 566
37. A.-M.J. Fichtinger-Schepman, A.T. van Oosterom, P.H.M. Lohman, and F. Berends cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis- diamminedichloroplatinum(II) Cancer Res 47 1987 3000 3004
38. A.-M.J. Fichtinger-Schepman, F.J. Dijt, P. Bedford, A.T. van Oosterom, B.T. Hill, and F. Berends Induction and removal of cisplatin-DNA adducts in human cells in vivo and in vitro as measured by immunochemical techniques IARC 1987 1988 321 328
39. B.T. Hill, S.A. Shellard, A.M. Fichtinger-Schepman, H.J. Schmoll, and A. Harstrick Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines Anticancer Drugs 5 1994 321 328
40. P. Bedford, A.-M.J. Fichtinger-Schepman, S.A. Shellard, M.C. Walker, J.R.W. Masters, and B.T. Hill Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines Cancer Res 48 1988 3019 3024
41. J.H.M. Schellens, J. Ma, A.S.Th. Planting, M.E.L. van der Burg, E. van Meerten, and M. de Boer-Dennert Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours Br J Cancer 73 1996 1569 1575
42. A. Bonetti, P. Apostoli, M. Zaninelli, F. Pavanel, M. Colombatti, and G.L. Cetto Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy Clin Cancer Res 2 1996 1829 1835
43. G.A.P. Hospers, E.G.E. de Vries, and N.H. Mulder The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell line Br J Cancer 61 1990 79 82
44. John T, Ottley CJ, Pearson DG, Nowell GM, Calvert AH, Tilby MJ. Determination by ICP-MS, of background and BBR 3464 induced levels of platinum bound to DNA isolated from blood cells: a comparison of the sensitivity of the Perkin-Elmer Sciex Elan 6000 and the ThermoFinnigan Neptune Instruments. In: Plasma source mass spectrometry. Special Publications, Royal Society of Chemistry; 2003. p. 82-90.